Prelude Therapeutics appoints Bryant D. Lim as permanent CFO; base salary $483K
Prelude Therapeutics Inc
Bryant D. Lim, previously interim CFO, appointed permanent CFO effective Feb 3, 2025; retains roles of Chief Legal Officer and Corporate Secretary.
Amended employment agreement provides base salary of $483,000, discretionary bonus up to 40% of base, and option for 200,000 shares vesting over 4 years.
Severance: nine months of base salary for termination without cause (non-change-of-control); twelve months for termination without cause or good reason related to change of control.
Option grant vests 25% on first anniversary and 1/48 monthly thereafter, subject to continued service.
On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Bryant D. Lim was appointed as Chief Financial Officer at Prelude Therapeutics Inc.
Action
appointed
Role
Chief Financial Officer
Exact text from the filing
On February 3, 2025 (the “Effective Date”), the Board approved the appointment of Mr. Lim as the Company’s permanent Chief Financial Officer, effective as of the Effective Date.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.